<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Flutamide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Flutamide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Flutamide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11369" href="/d/html/11369.html" rel="external">see "Flutamide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708803"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hepatic injury:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking flutamide. Evidence of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy and death related to acute hepatic failure. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately half of the reported cases occurred within the initial 3 months of treatment with flutamide.</p>
<p style="text-indent:-2em;margin-left:2em;">Serum transaminase levels should be measured prior to starting treatment with flutamide. Flutamide is not recommended in patients whose ALT values exceed twice the upper limit of normal. Serum transaminase levels should then be measured monthly for the first 4 months of therapy, and periodically thereafter. Liver function tests also should be obtained at the first signs and symptoms suggestive of liver dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, hyperbilirubinuria, jaundice, right upper quadrant tenderness). If at any time, a patient has jaundice, or their ALT rises above 2 times the upper limit of normal, flutamide should be immediately discontinued with close follow-up of liver function tests until resolution.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56417812"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Eulexin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866952"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>DOM-Flutamide</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F173288"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antiandrogen</li></ul></div>
<div class="block doa drugH1Div" id="F173249"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c307a68d-aa90-4809-92e4-ae972fb30608">Paraphilia, males</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paraphilia, males (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use as an adjunctive to prevent an acute increase in androgen concentrations when initiating gonadotropin-releasing hormone (GnRH) agonist therapy (eg, leuprolide, triptorelin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32452729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32452729'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>250 mg 3 times daily; initiate flutamide no later than the day GnRH agonist therapy is started and continue for 14 to 30 days following GnRH agonist initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11446201','lexi-content-ref-16362253','lexi-content-ref-32452729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11446201','lexi-content-ref-16362253','lexi-content-ref-32452729'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="562c2012-3943-4422-862c-4340368b07a8">Prostate cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic (alternate agent; in patients with low disease burden</b>
<b>):</b>
<b>Oral:</b> 250 mg 3 times daily (every 8 hours) in combination with a luteinizing hormone-releasing hormone agonist.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991770"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment is necessary in patients with chronic renal insufficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">Dialysis: Flutamide and the active metabolite are not well dialyzed; flutamide is not cleared by hemodialysis.</p></div>
<div class="block doha drugH1Div" id="F50989060"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment at baseline:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">ALT &gt;2 times ULN: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b> Jaundice or ALT &gt;2 times ULN: Discontinue flutamide immediately; monitor liver function closely until resolution.</p></div>
<div class="block doe drugH1Div" id="F173250"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F173216"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Endocrine &amp; metabolic: Hot flash (46% to 61%), galactorrhea (9% to 42%), decreased libido (36%), increased lactate dehydrogenase (transient; mild)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Diarrhea (12% to 40%), vomiting (11% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Genitourinary: Impotence (33%), cystitis (16%), breast tenderness</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hematologic &amp; oncologic: Rectal hemorrhage (14%), tumor flare</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hepatic: Increased serum AST (transient; mild)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardiovascular: Edema (4%), hypertension (1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Anxiety, confusion, depression, dizziness, drowsiness, headache, insomnia, nervousness </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Skin rash (3% to 8%), ecchymoses, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Endocrine &amp; metabolic: Gynecomastia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Nausea (9%), proctitis (8%), gastric distress (4% to 6%), anorexia (4%), constipation, dyspepsia, increased appetite</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Genitourinary: Hematuria (7%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hematologic &amp; oncologic: Anemia (6%), leukopenia (3%), thrombocytopenia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infection: Herpes zoster</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neuromuscular &amp; skeletal: Weakness (1%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%, postmarketing, and case reports: Cholestatic jaundice, hemolytic anemia, hepatic encephalopathy, hepatic failure, hepatic necrosis, hepatitis, hypersensitivity pneumonitis, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased serum ALT, increased serum bilirubin, increased serum creatinine, jaundice, macrocytic anemia, malignant neoplasm of breast (male), methemoglobinemia, myocardial infarction, oligospermia, pulmonary embolism, skin photosensitivity, sulfhemoglobinemia, thrombophlebitis, urine discoloration (amber, yellow-green)</p></div>
<div class="block coi drugH1Div" id="F173231"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to flutamide or any component of the formulation; severe hepatic impairment (evaluate baseline hepatic enzymes prior to treatment).</p></div>
<div class="block war drugH1Div" id="F173213"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aniline toxicity: 4-nitro-3-fluoro-methylaniline is a flutamide metabolite. Patients with G6PD deficiency, hemoglobin M disease, and/or smokers are at risk of toxicities associated with aniline exposure, including methemoglobinemia, hemolytic anemia, and cholestatic jaundice; consider monitoring methemoglobin levels.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gynecomastia: Gynecomastia may occur in patients receiving flutamide in combination with medical castration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Females: Flutamide is not indicated for use in females and should not be used in females, particularly for nonserious or non-life-threatening conditions.</p></div>
<div class="block foc drugH1Div" id="F173224"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eulexin: 125 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg [DSC]</p></div>
<div class="block geq drugH1Div" id="F173209"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F173233"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Eulexin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $35.94</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866953"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block adm drugH1Div" id="F173228"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered with or without food. Administer orally in 3 divided doses (every 8 hours).</p></div>
<div class="block hazard drugH1Div" id="F49104523"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F173227"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer (metastatic):</b> Management of locally confined Stage B<sub>2</sub> to C and Stage D<sub>2</sub> metastatic prostate cancer (in combination with a luteinizing hormone-releasing hormone [LHRH] agonist). For Stage B<sub>2</sub> to C prostate cancer, flutamide treatment (and goserelin) should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy. To achieve treatment benefit in Stage D<sub>2</sub> metastatic prostate cancer, initiate flutamide with the LHRH agonist and continue until disease progression.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Guideline recommendations:</i> The American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline for systemic therapy in men with metastatic castration-resistant prostate cancer suggests that data regarding the clinical benefit of older antiandrogens (including flutamide) are limited, and that older antiandrogen agents may be less efficacious compared to contemporary antiandrogen agents. However, older antiandrogen agents may be offered in patients with low prostate cancer disease burden or limited therapy options (ASCO [Basch 2014]).</p></div>
<div class="block off-label drugH1Div" id="F57849844"><span class="drugH1">Use: Off-Label: Adult</span><p>Paraphilia, males</p></div>
<div class="block mst drugH1Div" id="F173296"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Flutamide may be confused with apalutamide, bicalutamide, darolutamide, enzalutamide, Flumadine, nilutamide, thalidomide</p>
<p style="text-indent:-2em;margin-left:4em;">Eulexin may be confused with Edecrin, Eurax</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F173281"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F173218"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Antiandrogens may diminish the diagnostic effect of Flotufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of these therapies on the performance of flotufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Antiandrogens may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact on the performance of gallium Ga 68 PSMA-11 (gozetotide) is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Antiandrogens may diminish the diagnostic effect of Piflufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of these therapies on the performance of piflufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53715831"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Although flutamide is not indicated for use in females, it has been used off label for acne, hirsutism, polycystic ovary syndrome (PCOS), and female pattern hair loss in women. Due to the potential for serious toxicity and the availability of other treatment options, off-label use for these conditions is not recommended (Azarchi 2019; ES [Goodman 2015]); ES [Martin 2018]). Effective contraception is recommended if used in females for these conditions (Azarchi 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Women treated with flutamide for PCOS may have a return of regular menses and ovulatory cycles (Paradisi 2013).</p></div>
<div class="block pri drugH1Div" id="F14206271"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to flutamide may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F21206088"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">It is not known if flutamide is present in breast milk.</p></div>
<div class="block mop drugH1Div" id="F173222"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer:</b> Serum transaminases (at baseline, monthly for 4 months, and periodically thereafter); monitor LFTs at the first sign or symptom of liver dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, hyperbilirubinuria, jaundice, or right upper quadrant tenderness; if jaundice or ALT &gt;2 times ULN occurs, monitor LFTs closely until resolution); monitor prostate specific antigen (PSA). Consider monitoring methemoglobin levels in patients with hemoglobin M disease or with G6PD deficiency and in smokers. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiovascular monitoring for patients with prostate cancer:</b> Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; baseline and serial ECGs are recommended in patients at risk of QTc prolongation during androgen deprivation therapy (ADT); estimate 10-year cardiovascular disease risk in patients without cardiovascular disease at baseline; assess cardiovascular risk annually during ADT (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F173212"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Flutamide is a nonsteroidal antiandrogen that inhibits androgen uptake and/or inhibits binding of androgen in target tissues.</p></div>
<div class="block phk drugH1Div" id="F173230"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid and complete</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Parent drug: 94% to 96%; 2-hydroxyflutamide: 92% to 94%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic to ≥6 metabolites, primarily 2-hydroxyflutamide (active)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~6 hours (2-hydroxyflutamide [active metabolite])</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~2 hours (2-hydroxyflutamide [active metabolite])</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (as flutamide and metabolites); feces (~4%)</p></div>
<div class="block phksp drugH1Div" id="F51192624"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The half-life of the active metabolite is slightly prolonged in patients with CrCl &lt;29 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The half-life is prolonged to ~9.6 hours (active metabolite at steady state).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F173234"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Eulexin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Asoflut | Dedile | Eulexin | Flutamida | Flutamida filaxis | Flutamida gador | Flutamida martian | Flutamida microsules | Flutax | Flutepan | Flutrax</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Flutabene | Flutamid | Flutamid-ebewe | Flutastad | Fugerel</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutamin | Fugerel</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Proscan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutamide eurogenerics | Flutamide merck-generics | Flutaplex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Flucinom | Flutamida | Flutan | Flutasin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Biomida | Eulexin | Flutamid | Flutamida | Tecnoflut | Teflut</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Flucinom</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Drogenil | Etaconil | Flulem</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fugerel</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Etaconil | Eulexin | Flulem | Flutamida</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Andraxan | Apo flutamide | Flucinom | Flumed | Flutaplex | Prostandril</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Apimid | Flubloc | Flumid | Fluta | Fluta 1a pharma | Fluta cell | Flutamex | Flutamid | Flutamid 1a pharma | Flutamid al | Flutamid CT | Flutamid Kanoldt | Flutamid sandoz | Flutamide biosyn | Fugerel | Prostica | Prostogenat | Testotard</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Fluprosin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutamid | Fluxus</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Drogenil | Flutamida | Flutamida nifa | Fluxus</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Flucinom | Flutacan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Androxin | Androxine | Cytomid | Eulexin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutamida bayvit | Flutamida bexal | Flutamida bristol | Flutamida edigen | Flutamida elfar | Flutamida merck | Flutamida ratiopharm | Flutamida smaller | Flutandrona | Flutaplex | Grisetin | Oncosal | Prostacur</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutamid Abbott | Flutamid Stada | Profamid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Eulexine | Flutamide arrow | Flutamide biogaran | Flutamide cristers | Flutamide g gam | Flutamide ivax | Flutamide merck | Flutamide teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Chimax | Drogenil | Flutamide arrow | Flutamide cox | Flutamide kent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Elbat | Flucinom | Flutaplex | Palistop | Prostamide | Tremexal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo flutamide | Fugerel</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Flucinom | Prostandril</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Andraxan | Cytamid | Fluprost | Flutam | Flutamid Abbott | Flutamida sindan | Flutasin | Fugerel | Prosztika</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Flutaplex | Fugerel</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Androstat | Drogenil</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Eulexin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cytomid | Drogenil | Flutatec</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Drogenil | Eulexin | Fluprost | Flutamide alfa | Flutamide eg | Flutamide pht | Ricalide</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Curestat | Eulexin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Flutamerck | Flutamide Kobayashi | Flutamide yakult | Odyne</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Flutan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flexin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Eulexin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Flucinom | Flutamid CT | Flutamid rph | Flutan | Flutaplex</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutaplex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Flucinom | Flutan | Flutaplex | Profamid</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Eulexine | Flutam</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Damilfu | Eulexin | Fluken | Flulem | Flutepan | Tafenil | Tamidex</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Eumide | Fluta cell | Flutan | Fugerel</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Ag flutamide | G fluta | Lutamide | Tamid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Drogenil | Eulexin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutamid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutamide mylan | Flutamin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dedile | Etaconil | Flutamida</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Flutanon | Fugerel | Prostanon</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Flutacan | Flutamida | Fluten</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo-flutam | Flutamid | Fugerel | Prostandril</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Eulexin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutamida | Prosneo</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Flutamida cipla | Flutamida janvier | Flutamida whelp | Flutrax | Fluxus</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Curestat</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Flucinom | Flutamida sindan | Flutan | Flutasin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Andraxan | Aprokan | Flucinom | Flutamid | Flutamide pliva | Flutamide Sandoz | Flutamide stada | Flutamide tl | Flutaplex | Frugyl | Niftolid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo flutamide | Eulexin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutacan | Flutamid Abbott | Flutamid Copyfarm | Flutamid Mylan | Flutamid Orion | Flutamid Stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Flumid | Fugerel</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Flucinom</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Flucinom | Flutan | Flutaplex | Flutasin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Flulem | Flutan | Flutaplex | Fugerel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutamida gador</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Farostat | Fugerel | Fuprostate</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Flucinom | Flulem | Flumid | Flutafarm | Flutafarm femina | Flutan</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aprostil | Eulexin | Flutamida | Flutamida Lazar</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Etaconil | Eulexin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Eulexin | Flutahexal | Flutaplex | Spec Flutamide</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flutamide-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30312645">
<a name="30312645"></a>Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: Hormone-modulating therapies for skin disease. <i>J Am Acad Dermatol</i>. 2019;80(6):1509-1521. doi: 10.1016/j.jaad.2018.08.061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flutamide-drug-information/abstract-text/30312645/pubmed" id="30312645" target="_blank">30312645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25199761">
<a name="25199761"></a>Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448. doi: 10.1200/JCO.2013.54.8404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flutamide-drug-information/abstract-text/25199761/pubmed" id="25199761" target="_blank">25199761</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Eulexin (flutamide) capsules [prescribing information]. Wixon, MI: Waylis Therapeutics LLC; June 2021.</div>
</li>
<li>
<div class="reference">
                  Eulexintim (flutamide) capsules, USP [prescribing information]. Wixom, MI: Waylis Therapeutics LLC; June 2021.</div>
</li>
<li>
<div class="reference">
                  Flutamide [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26509855">
<a name="26509855"></a>Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome--part 1. <i>Endocr Pract</i>. 2015;21(11):1291-1300. doi: 10.4158/EP15748.DSC.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flutamide-drug-information/abstract-text/26509855/pubmed" id="26509855" target="_blank">26509855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11446201">
<a name="11446201"></a>Krueger RB, Kaplan MS. Depot-leuprolide acetate for treatment of paraphilias: a report of twelve cases. <i>Arch Sex Behav</i>. 2001;30(4):409-422. doi:10.1023/a:1010213432606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flutamide-drug-information/abstract-text/11446201/pubmed" id="11446201" target="_blank">11446201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124128">
<a name="20124128"></a>Levine GN, D'Amico AV, Berger P, et al; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. <i>Circulation.</i> 2010;121(6):833-840. doi: 10.1161/CIRCULATIONAHA.109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flutamide-drug-information/abstract-text/20124128/pubmed" id="20124128" target="_blank">20124128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flutamide-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522147">
<a name="29522147"></a>Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2018;103(4):1233-1257. doi: 10.1210/jc.2018-00241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flutamide-drug-information/abstract-text/29522147/pubmed" id="29522147" target="_blank">29522147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327685">
<a name="23327685"></a>Paradisi R, Fabbri R, Battaglia C, Venturoli S. Ovulatory effects of flutamide in the polycystic ovary syndrome. <i>Gynecol Endocrinol</i>. 2013;29(4):391-395. doi: 10.3109/09513590.2012.754876.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flutamide-drug-information/abstract-text/23327685/pubmed" id="23327685" target="_blank">23327685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16362253">
<a name="16362253"></a>Schober JM, Kuhn PJ, Kovacs PG, Earle JH, Byrne PM, Fries RA. Leuprolide acetate suppresses pedophilic urges and arousability. <i>Arch Sex Behav</i>. 2005;34(6):691-705. doi:10.1007/s10508-005-7929-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flutamide-drug-information/abstract-text/16362253/pubmed" id="16362253" target="_blank">16362253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32452729">
<a name="32452729"></a>Thibaut F, Cosyns P, Fedoroff JP, Briken P, Goethals K, Bradford JMW; WFSBP Task Force on Paraphilias. The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders. <i>World J Biol Psychiatry</i>. 2020;21(6):412-490. doi:10.1080/15622975.2020.1744723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flutamide-drug-information/abstract-text/32452729/pubmed" id="32452729" target="_blank">32452729</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8471 Version 261.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
